<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ911211-0029</DOCNO><DOCID>911211-0029.</DOCID><HL>   Business Brief -- Vestar Inc.:   DaunoXome May Be Able   To Treat Kaposi's Sarcoma</HL><DATE>12/11/91</DATE><SO>WALL STREET JOURNAL (J), PAGE B3</SO><CO>   VSTR</CO><MS>CONSUMER NON-CYCLICAL (NCY)</MS><IN>DRUG MANUFACTURERS (DRG)</IN><NS>SCIENCE andamp; TECHNOLOGY (SCN)</NS><RE>CALIFORNIA (CA)EUROPE (EU)FRANCE (FR)GERMANY (GE)NORTH AMERICA (NME)PACIFIC RIM (PRM)GREAT BRITAIN (UK)UNITED STATES (US)WESTERN EUROPE (WEU)</RE><LP>   Vestar Inc. said clinical results reported at a medicalmeeting indicate that its drug DaunoXome may have&quot;significant capability&quot; as a treatment for AIDS-relatedKaposi's sarcoma.   DaunoXome is a formulation of daunorubicin, an establishedcancer drug that previously wasn't used in AIDs patients.</LP><TEXT>   Vestar, based in San Dimas, Calif., reported to theAmerican Society of Hematology annual meeting that 60% of 16AIDS patients with Kaposi's sarcoma showed a reduction in thenumber, growth or size of lesions. And 40% showed astabilization of the cancer, Vestar said. DaunoXome can beused safely with AIDS patients who are also taking AZT,currently the principal treatment for AIDS patients, itreported.   Kaposi's sarcoma is characterized by lesions of the skin,mucous membranes, lymph nodes and internal organs. It affectsan estimated 15% or more of AIDS patients. Vestar develops,tests, manufactures and markets pharmaceuticals to treatpatients with cancer and serious infections, including AIDS.The company said it is doing clinical testing of DaunoXome inGermany, France, the United Kingdom, San Francisco and LosAngeles.</TEXT></DOC>